|
3D printing via reversible addition-fragmentation chain transfer (RAFT) polymerization has been recently developed to expand the scope of 3D printing technologies. A potentially high-impact but relatively unexplored opportunity that can be provided by RAFT-mediated 3D printing is a pathway toward personalized medicine through manufacturing bespoke drug delivery systems (DDSs). Herein, 3D printing of drug-eluting systems with precise geometry, size, drug dosage, and release duration/profiles is reported. This is achieved through engineering a range of 3D models with precise interconnected channel-pore structure and geometric proportions in architectural patterns. Notably, the application of the RAFT process is crucial in manufacturing materials with highly resolved macroscale features by confining curing to exposure precincts. This approach also allows spatiotemporal control of the drug loading and compositions within different layers of the scaffolds. The ratio between the polyethylene glycol units and the acrylate units in the crosslinkers is found to be a critical factor, with a higher ratio increasing swelling capacity, and thus enhancing the drug release profile, from the drug-eluting systems. This proof-of-concept research demonstrates that RAFT-mediated 3D printing enables the production of personalized drug delivery materials, providing a pathway to replace the “one-size-fits-all” approach in traditional health care. |
|